“`html
- Committed to net-zero across the value chain by 2050
- Aligned with 1.5°C mitigation pathways, the most ambitious SBTi designation
- Leader in Green CRDMO to drive innovation for a healthier future
SHANGHAI, Aug. 28, 2025 /PRNewswire/ — WuXi Biologics (2269.HK), a global powerhouse in the Contract Research, Development, and Manufacturing Organization (CRDMO) space, announced today a significant milestone in its sustainability journey: the Science Based Targets initiative (SBTi) has given its stamp of approval to the company’s near-term and net-zero greenhouse gas (GHG) emissions reduction targets. This move underscores WuXi Biologics’ commitment to leading the charge in environmental responsibility within the biopharmaceutical sector.
In a market increasingly scrutinizing ESG performance, WuXi Biologics distinguishes itself as one of the first CRDMOs to secure SBTi validation for both its near-term and long-term climate goals. The SBTi, a respected corporate climate action organization, champions ambitious emissions reductions, empowering companies and financial institutions to become active agents in combating climate change.
WuXi Biologics isn’t just paying lip service to sustainability; the company is implementing a comprehensive, target-driven strategy with a clearly defined roadmap. Building on its 2021 GHG emission intensity reduction target and 2022 operational net-zero goal, the company’s 2025 SBTi targets are aligned with the stringent 1.5°C pathways, covering Scope 1, 2, and 3 GHG emissions. The matrix includes ambitious near-term and net-zero goals demonstrating a holistic commitment.
Beyond its internal operations, WuXi Biologics is proactively engaging with suppliers to extend its sustainability initiatives across its entire value chain. This collaborative approach aims to create a ripple effect, fostering responsible practices and reducing the collective environmental footprint within the biopharmaceutical ecosystem.
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, sees the SBTi approval as a catalyst for further action. “We are delighted that our near-term and net-zero GHG targets have been approved by SBTi, an acknowledgement that further inspires our steadfast dedication to tackling climate change and leading the way to a net-zero economy,” stated Dr. Chen. “As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable partners worldwide with end-to-end solutions, and work together with all stakeholders to promote responsible practices.” This sentiment reflects the growing recognition that sustainability is not merely a corporate social responsibility, but a core driver of long-term value creation.
WuXi Biologics’ proactive approach to sustainability has garnered significant recognition within the ESG community. The company’s achievements include an MSCI AAA Rating, an EcoVadis Platinum Medal, a listing in the Dow Jones Sustainability Indices (DJSI), and consistent high rankings from CDP and Sustainalytics. These accolades are a testament to the company’s dedication to transparency, accountability, and continuous improvement in its ESG performance.
WuXi Biologics’ SBTi Target Matrix
Overall Net-Zero Target
Reach net-zero greenhouse gas emissions across the value chain by 2050.
Near-Term Targets
Reduce absolute scope 1 and 2 GHG emissions 58.8% by 2034 from a 2024 base year; reduce scope 3 GHG emissions covering purchased goods and services 63.8% per kg of product produced within the same timeframe.
Long-Term Targets
Reduce absolute scope 1 and 2 GHG emissions 90% by 2050 from a 2024 base year; reduce absolute scope 3 GHG emissions covering purchased goods and services, capital goods, fuel and energy-related activities, upstream transportation and distribution, waste generated in operations, and employee commuting 90% within the same timeframe.
About SBTi
The Science Based Targets initiative (SBTi) is a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis.
It develops standards, tools and guidance which allow companies to set greenhouse gas (GHG) emissions reductions targets in line with what is needed to keep global heating below catastrophic levels and reach net-zero by 2050 at latest.
The SBTi is incorporated as a charity, with a subsidiary which will host its target validation services. Its partners are CDP, the United Nations Global Compact, the We Mean Business Coalition, the World Resources Institute (WRI), and the World Wide Fund for Nature (WWF).
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2025, WuXi Biologics is supporting 864 integrated client projects, including 24 in commercial manufacturing.
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
“`
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/8186.html
